Calder Vale Peptides of Skipton closes after 21 years
A proper account of an operation that existed, and of what closing it cost.
The archive — 2026
Page 26 of 34 of this archive, newest first.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Chengdu export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Singapore health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
The convention nobody explains before handing over the vial
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
An interlaboratory comparison nobody had run
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 27% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What PeptideMeter charges to answer the pyrogen question
Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is…
The badge is about a sample. The listing is about a product.
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
From the floor in Shanghai: 22 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Independent analysis puts a SGN dulaglutide lot at 96.0%, against 93.3% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 22 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
The sample is not the batch
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Vitamin D, adiposity, and a volume-of-distribution problem
What the trials measured, which in the case of micronutrients is very little.
A shortage listing ends. 18 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
South Korea caps liraglutide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Target dose, effective dose, and the distance between them
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Reading the receptor: what distinguishes survodutide from liraglutide at the molecular level
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
Holding a dose is a decision, not a failure
Every major phase 3 protocol in this class allowed escalation to be delayed for tolerability. Almost no product label explains the mechanics of doing so.
The 25-day notice: how a compounding wind-down works in France
The document is four pages. Three of them are about dates.
REWIND extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Denmark caps tirzepatide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.